Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses

Daniel J. Landsburg, Stefan K. Barta, Radhakrishnan Ramchandren, Connie Batlevi, Swaminathan Iyer, Kevin Kelly, Ivana N. Micallef, Sonali M. Smith, Don A. Stevens, Mariano Alvarez, Andrea Califano, Yao Shen, Gideon Bosker, Jefferson Parker, Raul Soikes, Elizabeth Martinez, Reinhard von Roemeling, Robert E. Martell, Yasuhiro Oki

Research output: Contribution to journalArticlepeer-review

Abstract

Fimepinostat (CUDC-907), a first-in-class oral small-molecule inhibitor of histone deacetylase and phosphatidylinositol 3-kinase, demonstrated efficacy in a phase 1 study of patients with relapsed/refractory (R/R) diffuse large and high-grade B-cell lymphomas (DLBCL/HGBL), particularly those with increased MYC protein expression and/or MYC gene rearrangement/copy number gain (MYC-altered disease). Therefore, a phase 2 study of fimepinostat was conducted in this patient population with 66 eligible patients treated. The primary end-point of overall response (OR) rate for patients with MYC-IHC ≥40% (n = 46) was 15%. Subsequently, exploratory pooled analyses were performed including patients treated on both the phase 1 and 2 studies based upon the presence of MYC-altered disease as well as a biomarker identified by Virtual Inference of Protein activity by Enriched Regulon analysis (VIPER). For these patients with MYC-altered disease (n = 63), the overall response (OR) rate was 22% with seven responding patients remaining on treatment for approximately two years or longer, and VIPER yielded a three-protein biomarker classification with positive and negative predictive values of ≥85%. Prolonged durations of response were achieved by patients with MYC-altered R/R DLBCL/HGBL treated with single-agent fimepinostat. Combination therapies and/or biomarker-based patient selection strategies may lead to higher response rates in future clinical trials.

Original languageEnglish (US)
Pages (from-to)201-209
Number of pages9
JournalBritish journal of haematology
Volume195
Issue number2
DOIs
StatePublished - Oct 2021

Keywords

  • biomarker
  • diffuse large B-cell lymphoma
  • histone deacetylase inhibitor
  • MYC
  • phosphatidylinositol 3-kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses'. Together they form a unique fingerprint.

Cite this